{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:41:00Z","timestamp":1765485660006,"version":"3.40.4"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T00:00:00Z","timestamp":1355875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T00:00:00Z","timestamp":1355875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl."],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00103-012-1577-1","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T10:44:14Z","timestamp":1356777854000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Versorgung und Behandlung von EHEC\/HUS-Patienten","Management of patients with EHEC\/HUS"],"prefix":"10.1007","volume":"56","author":[{"given":"W.V.","family":"Kern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF01704889","volume":"20","author":"Walterspiel","year":"1992","unstructured":"Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG (1992) Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 20:25\u201329","journal-title":"Infection"},{"key":"1577_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/AAC.49.3.931-944.2005","volume":"49","author":"Herold","year":"2005","unstructured":"Herold S, Siebert J, Huber A, Schmidt H (2005) Global expression of prophage genes in Escherichia coli O157:H7 strain EDL933 in response to norfloxacin. Antimicrob Agents Chemother 49:931\u2013944","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s100960050181","volume":"17","author":"Grif","year":"1998","unstructured":"Grif K, Dierich MP, Karch H, Allerberger F (1998) Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 17:761\u2013766","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1577_CR4","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1128\/JCM.00871-08","volume":"46","author":"Pedersen","year":"2008","unstructured":"Pedersen MG, Hansen C, Riise E et al (2008) Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors. J Clin Microbiol 46:2987\u20132991","journal-title":"J Clin Microbiol"},{"key":"1577_CR5","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1128\/AAC.01783-09","volume":"54","author":"McGannon","year":"2010","unstructured":"McGannon CM, Fuller CA, Weiss AA (2010) Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother 54:3790\u20133798","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.11150\/kansenshogakuzasshi1970.71.130","volume":"71","author":"Ito","year":"1997","unstructured":"Ito T, Akino E, Hiramatsu K (1997) Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis \u2013 effect of various antibiotics on extracellular release of verotoxin. Kansenshogaku Zasshi 71:130\u2013135","journal-title":"Kansenshogaku Zasshi"},{"key":"1577_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1348-0421.2007.tb03926.x","volume":"51","author":"Jeon","year":"2007","unstructured":"Jeon B, Itoh K (2007) Production of shiga toxin by a luxS mutant of Escherichia coli O157:H7 in vivo and in vitro. Microbiol Immunol 51:391\u2013396","journal-title":"Microbiol Immunol"},{"key":"1577_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3201\/eid0605.000503","volume":"6","author":"Kimmitt","year":"2000","unstructured":"Kimmitt PT, Harwood CR, Barer MR (2000) Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 6:458\u2013465","journal-title":"Emerg Infect Dis"},{"key":"1577_CR9","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1128\/JB.181.7.2257-2260.1999","volume":"181","author":"Matsushiro","year":"1999","unstructured":"Matsushiro A, Sato K, Miyamoto H et al (1999) Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin. J Bacteriol 181:2257\u20132260","journal-title":"J Bacteriol"},{"key":"1577_CR10","first-page":"1238","volume":"19","author":"Lee","year":"2009","unstructured":"Lee JH, Stein BD (2009) Antimicrobials effective for inhibition of enterohaemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases. J Microbiol Biotechnol 19:1238\u20131243","journal-title":"J Microbiol Biotechnol"},{"key":"1577_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/j.1365-2672.2007.03692.x","volume":"104","author":"Maurer","year":"2008","unstructured":"Maurer C, Lazizzera C, Madec JY (2008) Characterization of inducible stx2-positive Escherichia coli O157:H7\/H7-strains isolated from cattle in France. J Appl Microbiol 104:1569\u20131576","journal-title":"J Appl Microbiol"},{"key":"1577_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/fpd.2008.0165","volume":"6","author":"Maurer","year":"2009","unstructured":"Maurer C, Meunier D, Madec JY (2009) Shiga toxin Stx2 production is promoted by enrofloxacin in experimental in vitro-selected mutants of Escherichia coli O157:H7 resistant to fluoroquinolones. Foodborne Pathog Dis 6:257\u2013259","journal-title":"Foodborne Pathog Dis"},{"key":"1577_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1086\/315239","volume":"181","author":"Zhang","year":"2000","unstructured":"Zhang X, McDaniel AD, Wolf LE et al (2000) Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 181:664\u2013670","journal-title":"J Infect Dis"},{"key":"1577_CR14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1139\/w99-069","volume":"45","author":"Yoh","year":"1999","unstructured":"Yoh M, Frimpong EK, Voravuthikunchai SP, Honda T (1999) Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Can J Microbiol 45:732\u2013739","journal-title":"Can J Microbiol"},{"key":"1577_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1106920","volume":"365","author":"Rasko","year":"2011","unstructured":"Rasko DA, Webster DR, Sahl JW et al (2011) Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365:709\u2013717","journal-title":"N Engl J Med"},{"key":"1577_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1017\/S0950268897007541","volume":"119","author":"Yoh","year":"1997","unstructured":"Yoh M, Honda T (1997) The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production\/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Epidemiol Infect 119:101\u2013103","journal-title":"Epidemiol Infect"},{"key":"1577_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1574-695X.1997.tb01072.x","volume":"19","author":"Yoh","year":"1997","unstructured":"Yoh M, Frimpong EK, Honda T (1997) Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol 19:57\u201364","journal-title":"FEMS Immunol Med Microbiol"},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jac\/42.3.341","volume":"42","author":"Izumikawa","year":"1998","unstructured":"Izumikawa K, Hirakata Y, Yamaguchi T et al (1998) Escherichia coli O157 interactions with human intestinal Caco-2 cells and the influence of fosfomycin. J Antimicrob Chemother 42:341\u2013347","journal-title":"J Antimicrob Chemother"},{"key":"1577_CR19","first-page":"691","volume":"56","author":"Takata","year":"2003","unstructured":"Takata T, Tabata M, Tsuruoka T, Watabe H (2003) Activity of fosfomycin against Escherichia coli O157:H7-morphological changes and production of Shiga toxins. Jpn J Antibiot 56:691\u2013696","journal-title":"Jpn J Antibiot"},{"key":"1577_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1292\/jvms.66.899","volume":"66","author":"Uemura","year":"2004","unstructured":"Uemura R, Sueyoshi M, Taura Y, Nagatomo H (2004) Effect of antimicrobial agents on the production and release of shiga toxin by enterotoxaemic Escherichia coli isolates from pigs. J Vet Med Sci 66:899\u2013903","journal-title":"J Vet Med Sci"},{"key":"1577_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/fpd.2009.0311","volume":"7","author":"Mohsin","year":"2010","unstructured":"Mohsin M, Haque A (2010) Effects of ampicillin, gentamicin, and cefotaxime on the release of Shiga toxins from Shiga toxin-producing Escherichia coli isolated during a diarrhea episode in Faisalabad, Pakistan. Foodborne Pathog Dis 7:85\u201390","journal-title":"Foodborne Pathog Dis"},{"key":"1577_CR22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1128\/AAC.41.10.2295","volume":"41","author":"Takahashi","year":"1997","unstructured":"Takahashi K, Narita K, Kato Y et al (1997) Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother 41:2295\u20132296","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR23","first-page":"541","volume":"52","author":"Nasu","year":"1999","unstructured":"Nasu T, Okamoto K, Nakanishi T, Nishino T (1999) In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains. Jpn J Antibiot 52:541\u2013553","journal-title":"Jpn J Antibiot"},{"key":"1577_CR24","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1128\/AAC.06315-11","volume":"56","author":"Bielaszewska","year":"2012","unstructured":"Bielaszewska M, Idelevich EA, Zhang W et al (2012) Effects of antibiotics on shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 56:3277\u20133282","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR25","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.46.11.3478-3483.2002","volume":"46","author":"Ohara","year":"2002","unstructured":"Ohara T, Kojio S, Taneike I et al (2002) Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 46:3478\u20133483","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0924-8579(00)00126-6","volume":"15","author":"Murakami","year":"2000","unstructured":"Murakami J, Kishi K, Hirai K et al (2000) Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents 15:103\u2013109","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.bbrc.2003.09.145","volume":"310","author":"Nakagawa","year":"2003","unstructured":"Nakagawa S, Kojio S, Taneike I et al (2003) Inhibitory action of telithromycin against Shiga toxin and endotoxin. Biochem Biophys Res Commun 310:1194\u20131199","journal-title":"Biochem Biophys Res Commun"},{"key":"1577_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1086\/596509","volume":"199","author":"Zhang","year":"2009","unstructured":"Zhang Q, Donohue-Rolfe A, Krautz-Peterson G et al (2009) Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis 199:486\u2013493","journal-title":"J Infect Dis"},{"key":"1577_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0924-8579(03)00007-4","volume":"21","author":"Hiramatsu","year":"2003","unstructured":"Hiramatsu K, Murakami J, Kishi K et al (2003) Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection. Int J Antimicrob Agents 21:471\u2013477","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1179\/000349803235002146","volume":"97","author":"Matar","year":"2003","unstructured":"Matar GM, Rahal E (2003) Inhibition of the transcription of the Escherichia coli O157:H7 genes coding for shiga-like toxins and intimin, and its potential use in the treatment of human infection with the bacterium. Ann Trop Med Parasitol 97:281\u2013287","journal-title":"Ann Trop Med Parasitol"},{"key":"1577_CR31","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1128\/AAC.01397-06","volume":"51","author":"Ochoa","year":"2007","unstructured":"Ochoa TJ, Chen J, Walker CM et al (2007) Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 51:2837\u20132841","journal-title":"Antimicrob Agents Chemother"},{"key":"1577_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijantimicag.2010.10.009","volume":"37","author":"Rahal","year":"2011","unstructured":"Rahal EA, Kazzi N, Kanbar A et al (2011) Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB\/c mice. Int J Antimicrob Agents 37:135\u2013139","journal-title":"Int J Antimicrob Agents"},{"key":"1577_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1476-0711-10-34","volume":"10","author":"Rahal","year":"2011","unstructured":"Rahal EA, Kazzi N, Sabra A et al (2011) Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157:H7-infected BALB\/c mice. Ann Clin Microbiol Antimicrob 10:34","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1577_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s100960050348","volume":"18","author":"Kurioka","year":"1999","unstructured":"Kurioka T, Yunou Y, Harada H, Kita E (1999) Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Eur J Clin Microbiol Infect Dis 18:561\u2013671","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1577_CR35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.11150\/kansenshogakuzasshi1970.73.1054","volume":"73","author":"Sawamura","year":"1999","unstructured":"Sawamura S, Tanaka K, Koga Y (1999) Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: in vivo analysis using germfree mice. Kansenshogaku Zasshi 73:1054\u20131063","journal-title":"Kansenshogaku Zasshi"},{"key":"1577_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1574-695X.1999.tb01376.x","volume":"26","author":"Yoshimura","year":"1999","unstructured":"Yoshimura K, Fujii J, Taniguchi H, Yoshida S (1999) Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. FEMS Immunol Med Microbiol 26:101\u2013108","journal-title":"FEMS Immunol Med Microbiol"},{"key":"1577_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1348-0421.2000.tb01251.x","volume":"44","author":"Isogai","year":"2000","unstructured":"Isogai E, Isogai H, Hayashi S et al (2000) Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol Immunol 44:89\u201395","journal-title":"Microbiol Immunol"},{"key":"1577_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0022-3476(05)81209-0","volume":"121","author":"Proulx","year":"1992","unstructured":"Proulx F, Turgeon JP, Delage G et al (1992) Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 121:299\u2013303","journal-title":"J Pediatr"},{"key":"1577_CR39","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jama.288.8.996","volume":"288","author":"Safdar","year":"2002","unstructured":"Safdar N, Said A, Gangnon RE, Maki DG (2002) Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288:996\u20131001","journal-title":"JAMA"},{"key":"1577_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/bmj.330.7488.409","volume":"330","author":"Phillips","year":"2005","unstructured":"Phillips B, Tyerman K, Whiteley SM (2005) Use of antibiotics in suspected haemolytic-uraemic syndrome. BMJ 330:409\u2013410","journal-title":"BMJ"},{"key":"1577_CR41","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1365-2036.2006.03036.x","volume":"24","author":"Panos","year":"2006","unstructured":"Panos GZ, Betsi GI, Falagas ME (2006) Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 24:731\u2013742","journal-title":"Aliment Pharmacol Ther"},{"key":"1577_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10157-007-0007-4","volume":"12","author":"Iijima","year":"2008","unstructured":"Iijima K, Kamioka I, Nozu K (2008) Management of diarrhea-associated hemolytic uremic syndrome in children. Clin Exp Nephrol 12:16\u201319","journal-title":"Clin Exp Nephrol"},{"key":"1577_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/MOG.0b013e3282f2dfb8","volume":"24","author":"Serna","year":"2008","unstructured":"Serna A, Boedeker EC (2008) Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 24:38\u201347","journal-title":"Curr Opin Gastroenterol"},{"key":"1577_CR44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1055\/s-0030-1262881","volume":"36","author":"Bitzan","year":"2010","unstructured":"Bitzan M, Schaefer F, Reymond D (2010) Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost 36:594\u2013610","journal-title":"Semin Thromb Hemost"},{"key":"1577_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1741-7015-10-12","volume":"10","author":"Goldwater","year":"2012","unstructured":"Goldwater PN, Bettelheim KA (2012) Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS). BMC Med 10:12","journal-title":"BMC Med"},{"key":"1577_CR46","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1128\/AEM.00217-12","volume":"78","author":"Muniesa","year":"2012","unstructured":"Muniesa M, Hammerl JA, Hertwig S et al (2012) Shiga toxin-producing Escherichia coli O104:H4 \u2013 a new challenge for microbiology. Appl Environ Microbiol 78:4065\u20134073","journal-title":"Appl Environ Microbiol"},{"key":"1577_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1086\/499236","volume":"42","author":"Bennish","year":"2006","unstructured":"Bennish ML, Khan WA, Begum M et al (2006) Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 42:356\u2013362","journal-title":"Clin Infect Dis"},{"key":"1577_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3201\/eid0104.950407","volume":"1","author":"Al-Qarawi","year":"1995","unstructured":"Al-Qarawi S, Fontaine RE, Al-Qahtani MS (1995) An outbreak of hemolytic uremic syndrome associated with antibiotic treatment of hospital inpatients for dysentery. Emerg Infect Dis 1:138\u2013140","journal-title":"Emerg Infect Dis"},{"key":"1577_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3201\/eid0104.950406","volume":"1","author":"Bin","year":"1995","unstructured":"Bin Saeed AA, El-Bushra HE, Al-Hamdan NA (1995) Does treatment of bloody diarrhea due to Shigella dysenteriae type 1 with ampicillin precipitate hemolytic uremic syndrome? Emerg Infect Dis 1:134\u2013137","journal-title":"Emerg Infect Dis"},{"key":"1577_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1442-200X.1999.4121038.x","volume":"41","author":"Shiomi","year":"1999","unstructured":"Shiomi M, Togawa M, Fujita K, Murata R (1999) Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Int 41:228\u2013232","journal-title":"Pediatr Int"},{"key":"1577_CR51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1086\/313668","volume":"30","author":"Miedouge","year":"2000","unstructured":"Miedouge M, Hacini J, Grimont F, Watine J (2000) Shiga toxin-producing Escherichia coli urinary tract infection associated with hemolytic-uremic syndrome in an adult and possible adverse effect of ofloxacin therapy. Clin Infect Dis 30:395\u2013396","journal-title":"Clin Infect Dis"},{"key":"1577_CR52","first-page":"821","volume":"50","author":"Chisaki","year":"1997","unstructured":"Chisaki T, Hinotani K, Shimizu T, Miyazaki K (1997) Initial treatment at an outbreak of E. coli O-157:H7 infection: especially with respect to therapy in the emergency. Jpn J Antibiot 50:821\u2013828","journal-title":"Jpn J Antibiot"},{"key":"1577_CR53","unstructured":"Geerdes-Fenge H, N\u00fcrnberg M, Fritzsche C et al (2012) E. coli O104:H4-Infektion: Auswirkung antibiotischer Therapie auf die Entwicklung eines HUS. 11. Kongress f\u00fcr Infektionskrankheiten und Tropenmedizin, K\u00f6ln, abstract#P91"},{"key":"1577_CR54","first-page":"357","volume":"52","author":"Ikeda","year":"1999","unstructured":"Ikeda K, Ida O, Kimoto K, Takatorige T et al (1999) Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 52:357\u2013362","journal-title":"Clin Nephrol"},{"key":"1577_CR55","first-page":"591","volume":"50","author":"Moriguchi","year":"1997","unstructured":"Moriguchi N, Yagi K, Yamamoto T et al (1997) The drug sensitivity of enterohemorragic Escherichia coli and antibiotics treatment for hemorrhagic enterocolitis \u2013 from an outbreak of enterocolitis in Sakai city. Jpn J Antibiot 50:591\u2013596","journal-title":"Jpn J Antibiot"},{"key":"1577_CR56","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1086\/322598","volume":"33","author":"Dundas","year":"2001","unstructured":"Dundas S, Todd WT, Stewart AI et al (2001) The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 33:923\u2013931","journal-title":"Clin Infect Dis"},{"key":"1577_CR57","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","volume":"342","author":"Wong","year":"2000","unstructured":"Wong CS, Jelacic S, Habeeb RL et al (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930\u20131936","journal-title":"N Engl J Med"},{"key":"1577_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/INF.0b013e31823096a8","volume":"31","author":"Smith","year":"2012","unstructured":"Smith KE, Wilker PR, Reiter PL et al (2012) Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 31:37\u201341","journal-title":"Pediatr Infect Dis J"},{"key":"1577_CR59","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3201\/eid1104.040833","volume":"11","author":"Lynn","year":"2005","unstructured":"Lynn RM, O\u2019Brien SJ, Taylor CM et al (2005) Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11:590\u2013596","journal-title":"Emerg Infect Dis"},{"key":"1577_CR60","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jama.2012.264","volume":"307","author":"Nitschke","year":"2012","unstructured":"Nitschke M, Sayk F, H\u00e4rtel C et al (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307:1046\u20131052","journal-title":"JAMA"},{"key":"1577_CR61","doi-asserted-by":"publisher","first-page":"e4565","DOI":"10.1136\/bmj.e4565","volume":"345","author":"Menne","year":"2012","unstructured":"Menne J, Nitschke M, Stingele R et al (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. Brit Med J 345:e4565","journal-title":"Brit Med J"},{"key":"1577_CR62","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","volume":"53","author":"Michael","year":"2008","unstructured":"Michael M, Elliott EJ, Craig JC et al (2008) Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 53:259\u2013272","journal-title":"Am J Kidney Dis"},{"key":"1577_CR63","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(11)61145-8","volume":"378","author":"Colic","year":"2011","unstructured":"Colic E, Dieperink H, Titlestad K, Tepel M (2011) Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 378:1089\u20131093","journal-title":"Lancet"},{"key":"1577_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(12)60223-2","volume":"379","author":"Birn","year":"2012","unstructured":"Birn H, Ivarsen P, Svensson M et al (2012) Should all adult patients with diarrhoea-associated HUS receive plasma exchange? Lancet 379:515\u2013516","journal-title":"Lancet"},{"key":"1577_CR65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00467-011-2067-7","volume":"27","author":"Kemper","year":"2012","unstructured":"Kemper MJ (2012) Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 27:161\u2013164","journal-title":"Pediatr Nephrol"},{"key":"1577_CR66","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1093\/ndt\/gfq395","volume":"26","author":"Kielstein","year":"2011","unstructured":"Kielstein T (2011) The German 2011 epidemic of Shiga toxin-producing E. coli \u2013 the nephrological view. Nephrol Dial Transplant 26:2723\u20132726","journal-title":"Nephrol Dial Transplant"},{"key":"1577_CR67","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","volume":"378","author":"Greinacher","year":"2011","unstructured":"Greinacher A, Friesecke S, Abel P et al (2011) Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 378:1166\u20131173","journal-title":"Lancet"},{"key":"1577_CR68","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561\u20132563","journal-title":"N Engl J Med"},{"key":"1577_CR69","first-page":"539","volume":"Today","author":"Zareb","year":"2007","unstructured":"Zareb KM (2007) Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria. Drugs Today (Barc) 43:539\u2013546","journal-title":"Drugs"},{"key":"1577_CR70","unstructured":"Nature Medicine, 30.03.2012. Small biotechs raring to cash in on the orphan disease market. http:\/\/www.lavoiegroup.com\/featured-coverage\/aegerion-pharmaceuticals-profiled-in-nature-medicine.html"},{"key":"1577_CR71","unstructured":"Nature, 27.05.2011. German E. coli outbreak leads to drug trial \u2013 timely discovery of new use for expensive drug put to the test. http:\/\/www.nature.com\/news\/2011\/110527\/full\/news.2011.332.html?WT.mc_id=TWT_NatureNews&utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+yahoo%2FqUaz+%28Nature+news%29&utm_content=Twitter"},{"key":"1577_CR72","unstructured":"Spiegel International, 06.06.2011. Doctors use untested medication for deadly E. coli. http:\/\/www.spiegel.de\/international\/germany\/we-cannot-stand-by-and-watch-them-die-doctors-use-untested-medication-for-deadly-e-coli-a-766918.html"},{"key":"1577_CR73","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/CMR.00048-09","volume":"23","author":"Ram","year":"2010","unstructured":"Ram S, Lewis LA, Rice PA (2010) Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 23:740\u2013780","journal-title":"Clin Microbiol Rev"},{"key":"1577_CR74","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/INF.0b013e3182503849","volume":"31","author":"Gleesing","year":"2012","unstructured":"Gleesing J, Chiwane S, Rongkavilit C (2012) Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J 31:543","journal-title":"Pediatr Infect Dis J"},{"key":"1577_CR75","doi-asserted-by":"crossref","unstructured":"Fraser A, Gafter-Gvili A, Paul M, Leibovici L (2006) Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev CD004785","DOI":"10.1002\/14651858.CD004785.pub3"},{"key":"1577_CR76","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/00006454-199809000-00013","volume":"17","author":"Girgis","year":"1998","unstructured":"Girgis N, Sultan Y, Frenck RW et al (1998) Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 17:816\u2013819","journal-title":"Pediatr Infect Dis J"},{"key":"1577_CR77","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/01.olq.0000204675.92459.3c","volume":"33","author":"Dan","year":"2006","unstructured":"Dan M, Poch F, Amitai Z et al (2006) Pharyngeal gonorrhea in female sex workers: response to a single 2-g dose of azithromycin. Sex Transm Dis 33:512\u2013515","journal-title":"Sex Transm Dis"},{"key":"1577_CR78","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/sti.2010.044586","volume":"86","author":"Bignell","year":"2010","unstructured":"Bignell C, Garley J (2010) Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 86:422\u2013426","journal-title":"Sex Transm Infect"},{"key":"1577_CR79","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/jac\/45.6.909","volume":"45","author":"Simmons","year":"2000","unstructured":"Simmons G, Jones N, Calder L (2000) Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of serogroup B Neisseria meningitidis. J Antimicrob Chemother 45:909\u2013911","journal-title":"J Antimicrob Chemother"},{"key":"1577_CR80","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0140-6736(88)92069-7","volume":"358","author":"Schwartz","year":"1988","unstructured":"Schwartz B, Al-Tobaiqi A, Al-Ruwais A et al (1988) Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis. Lancet 358:1239\u20131242","journal-title":"Lancet"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-012-1577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-012-1577-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-012-1577-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-012-1577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:13:51Z","timestamp":1744172031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-012-1577-1"}},"subtitle":["Erfahrungen und Perspektiven aus infektiologischer Sicht","Lessons and perspectives from clinical infectious disease specialists"],"short-title":[],"issued":{"date-parts":[[2012,12,19]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s00103-012-1577-1","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"type":"print","value":"1436-9990"},{"type":"electronic","value":"1437-1588"}],"subject":[],"published":{"date-parts":[[2012,12,19]]},"assertion":[{"value":"19 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}